I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 335368880 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 30, 2004

Docket No. 304142000321

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Malaya CHATTERJEE et al.

Serial No.:

08/766,350

Filing Date:

December 13, 1996

For:

MURINE ANTI-IDIOTYPE ANTIBODY

11D10 AND METHODS OF USE

THEREOF

Examiner: S. Rawlings

Group Art Unit: 1642

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

07/07/2004 NROCHA1 00000017 031952 08766350

02 FC:1806

180.00 DA

	This S	Supplemental Information Disclosure Statement is submitted:
	Withi	n three months of the application filing date or before mailing of a first
	Office	e Action on the merits; accordingly, no fee or separate requirements are
	requir	red.
\boxtimes	After	receipt of a first Office Action on the merits but before mailing of a final
	Office	e Action or Notice of Allowance.
		A fee is required. A check in the amount of * is enclosed.
	\boxtimes	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is
		attached to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly;
		no fee is believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment
	of the	issue fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in
		the amount of * is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee
		Transmittal form (PTO/SB/17 is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for

any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 304142000321. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: <u>6/30</u>, 2004

Respectfully submitted,

By: July foctor Jilly A. Jacobson Registration No. 40,030 Morrison & Foerster LLP 755 Page Mill Road

Palo Alto, California 94304-1018

Telephone: (650) 813-5876 Facsimile: (650) 494-0792

Form PTO-1449
INFO MATION DISCLOSURE CITATION
IN AN APPLICATION
(Use several sheets if necessary)
and E
Maguery of the second
- Control of the Cont

	Sheet 1 of 2					
Docket Number 304142000321	Application Number 08/766,350					
Applicant						
Malaya CHATTERJEE et al						
Filing Date December 13, 1996 Group Art Unit 1642						
Mailing Date June 30, 2004						

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	08/14/2001	6,274,143	Chatterjee et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Transla YES	ition NO
	2.	08/08/1991	WO 91/11508	WIPO				
	3.	05/29/1992	WO 92/08495	WIPO				
	4.	05/23/2002	WO 02/40501	WIPO				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

		, , , , , , , , , , , , , , , , , , , ,
Examiner Initials	Ref. No.	Title
	5.	Amalfitano, A.et al. (2002). "Separating Fact From Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy," Current Gene Therapy 2(2):111-133.
	6.	Benvenuti, F. et al. (2000). "Anti-idiotypic DNA Vaccines for Lymphoma Immunotherapy Require the Presence of Both Variable Region Genes for Tumor Protection," <i>Gene Therapy</i> 7(7):605-611.
	7.	Benvenuti, F. et al. (2001). "Anti-idiotypic Antibodies Induced by Genetic Immunisation are Directed Exclusively Against Combined VL/VH Determinants," <i>Gene Therapy</i> 8(20):1555-1561.
	8.	Berzoksky, J.A. and Berkower, I.I. (1993). "Immunogencity and Antigen Structure," Chapter 8 <i>In</i> Fundamental Immunology, William E. Paul ed., Raven Press NY, page 242.
	9.	Bodey, B. et al. (2000). "Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy," <i>Anticancer Research</i> 20:2665-2676.
	10.	Browning, J. L. et al. (1993). "Lymphotoxin β , a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface," <i>Cell</i> (72):847-856.
	11.	Darsley, M. J. et al. (1985). "Nucleotide Sequences of Five Anti-Lysozyme Monoclonal Antibodies," <i>EMBO J.</i> 4(2):393-398.
	12.	De Waele, P. et al. (1988). "Expression in Non-Lymphoid Cells of Mouse Recombinant Immunoglobulin Directed Against The Tumour Marker Human Placental Alkaline Phosphatase," Eur. J. Biochem. 176:287-295.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

pa- 746601

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449			Docket Number 304142000321	Application Number 08/766,350				
OINFORM	MΑ	TION DISCLOSURE CITATION	Applicant	···				
in an application			Malaya CHATTERJEE et al					
JUN 3 0 2004	2	(Use several sheets if necessary)	Filing Date December 13, 1996	Group Art Unit 1642				
			Mailing Date June 30, 2004	-				
PADEMARY								
	13.	Gavilondo, J.V. et al. (2000). "Antiboo 145.	dy Engineering at the Millenni	um," Biotechiques 29(1): 128-				
	14.	Houdebine, L-M. (1994). "Production Journal of Biotechnology 34:269-287.						
	15.	Kavaler, J. et al. (1990). "A Set of Clo Response To The Antigenic Site CB o 145(7):2312-2321.						
	16.	Kennedy, R. C. et al. (1985). "Vaccine Mimic Antigens of Infectious Organis						
	17.	Liu, A. Y. et al. (1987). "Production o With Potent Fc-Dependent Biologic A						
	18.	Mo, J. A. et al. (1993). "Variable Regi With Specificity For a Defined Epitop						
	19.	Pandha, H. S et al. (2000). "Oncologia Investigation Drugs 1(1):122-134.	Pandha, H. S et al. (2000). "Oncologial Applications of Gene Therapy," Current Opinion in Investigation Drugs 1(1):122-134.					
	20.		Pandya, K. J. et al. (1985). "A Retrospective Study of Earliest Indicators of Recurrence in Patients On Eastern Cooperative Oncology Group Adjuvant Chemotherapy Trials For Breast Cancer. A					
	21.		Patterson, A. P. (2003). "Principles Investigators for Human Gene Transfer Trials Employing Retroviral Vectors. Notification of a Serious Adverse Event. Department of Health and Human					
	22.	Reeck et al. (1987). "Homology," Pro of It," <i>Cell</i> 50(5):667.	tein and Nucleic Acids: A Terr	minology Muddle and Way out				
	23.	Schouten, D. et al. (1993). "Developm High Density Lipoproteins," <i>Molecula</i>						
	24.	Seidman, J. G. et al. (1979). "A κ-Imm without Further Somatic Mutation," N		by Site-Specific Recombination				
	25.	Shlomchik, M. et al. (1990). "Anti-DNA Antibodies from Autoimmune Mice Arise by Clonal Expansion and Somatic Mutation," <i>J. Exp. Med.</i> 171(1):265-297.						
	26.	Stevenson, F. K. et al. (1995). "Idiotypic DNA Vaccines Against B-Cell Lymphoma," <i>Immunological Reviews</i> 145:211-228.						
	27.	Zeytin, H. E. et al. (2000). "Construction and Characterization of DNA Vaccines Encoding the Single-Chain Variable Fragment of the Anti-Idiotype Antibody 1A7 Mimicking the Tumor-Associated Antigen Disialoganglioside GD2," Cancer Gene Ther. 7(11):1426-1436.						
	28.	Verma, I. M. et al. (1997). "Gene The	rapy-Promises, Problems and	Prospects," <i>Nature</i> 389:239-242.				
EXAMIN	ER:		DATE CONSIDERED:					
		nitial if citation considered, whether or not the citati		a line through the citation if not in				